JP7660066B2 - 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム - Google Patents

膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム Download PDF

Info

Publication number
JP7660066B2
JP7660066B2 JP2021551622A JP2021551622A JP7660066B2 JP 7660066 B2 JP7660066 B2 JP 7660066B2 JP 2021551622 A JP2021551622 A JP 2021551622A JP 2021551622 A JP2021551622 A JP 2021551622A JP 7660066 B2 JP7660066 B2 JP 7660066B2
Authority
JP
Japan
Prior art keywords
bladder
chondroitin sulfate
distilled water
added
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021551622A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021066175A5 (cg-RX-API-DMAC7.html
JPWO2021066175A1 (cg-RX-API-DMAC7.html
Inventor
宗外 成田
健祐 石井
明人 志村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seikagaku Corp
Original Assignee
Seikagaku Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seikagaku Corp filed Critical Seikagaku Corp
Publication of JPWO2021066175A1 publication Critical patent/JPWO2021066175A1/ja
Publication of JPWO2021066175A5 publication Critical patent/JPWO2021066175A5/ja
Priority to JP2025059920A priority Critical patent/JP2025094276A/ja
Application granted granted Critical
Publication of JP7660066B2 publication Critical patent/JP7660066B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2021551622A 2019-10-03 2020-10-02 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム Active JP7660066B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025059920A JP2025094276A (ja) 2019-10-03 2025-03-31 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019183082 2019-10-03
JP2019183082 2019-10-03
PCT/JP2020/037640 WO2021066175A1 (ja) 2019-10-03 2020-10-02 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025059920A Division JP2025094276A (ja) 2019-10-03 2025-03-31 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤

Publications (3)

Publication Number Publication Date
JPWO2021066175A1 JPWO2021066175A1 (cg-RX-API-DMAC7.html) 2021-04-08
JPWO2021066175A5 JPWO2021066175A5 (cg-RX-API-DMAC7.html) 2023-10-02
JP7660066B2 true JP7660066B2 (ja) 2025-04-10

Family

ID=75338281

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021551622A Active JP7660066B2 (ja) 2019-10-03 2020-10-02 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム
JP2025059920A Pending JP2025094276A (ja) 2019-10-03 2025-03-31 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025059920A Pending JP2025094276A (ja) 2019-10-03 2025-03-31 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤

Country Status (4)

Country Link
US (1) US20220370630A1 (cg-RX-API-DMAC7.html)
EP (1) EP4039279A4 (cg-RX-API-DMAC7.html)
JP (2) JP7660066B2 (cg-RX-API-DMAC7.html)
WO (1) WO2021066175A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023034903A1 (en) * 2021-09-01 2023-03-09 3Helix, Inc. Systems and methods for detecting fibrosis

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005458A1 (ja) 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
JP2017036455A (ja) 2015-01-09 2017-02-16 生化学工業株式会社 コンドロイチン硫酸誘導体及び膀胱疾患処置剤

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083933A (en) * 1999-04-19 2000-07-04 Stellar International Inc. Treatment of cystitis-like symptoms with chondroitin sulfate following administration of a challenge solution
US20080306022A1 (en) 2005-10-12 2008-12-11 Kenji Miyamoto Agent for Applying to Mucosa and Method for the Production Thereof
US20150250717A1 (en) * 2014-03-06 2015-09-10 Taris Biomedical Llc Drug delivery systems and methods for treatment of bladder cancer with gemcitabine
JP7067229B2 (ja) 2018-04-17 2022-05-16 信越化学工業株式会社 反応性ケイ素含有基を有するポリマーおよびその製造方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015005458A1 (ja) 2013-07-10 2015-01-15 生化学工業株式会社 グリコサミノグリカン誘導体及びその製造方法
JP2017036455A (ja) 2015-01-09 2017-02-16 生化学工業株式会社 コンドロイチン硫酸誘導体及び膀胱疾患処置剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ONISHI, H. et al.,Conjugate between Chondroitin Sulfate and Prednisolone with Glycine Linker: Preparation and in Vitro Conversion Analysis,Chem. Pharm. Bull.,2013年,Vol.61, No.9,pp.902-912
宮本葵ほか,液体クロマトグラフィー/質量分析法を用いる環境水中副腎皮質ステロイド類分析法の開発,BUNSEKI KAGAKU,2010年,Vol.59, No.4,pp.301-309

Also Published As

Publication number Publication date
EP4039279A1 (en) 2022-08-10
JP2025094276A (ja) 2025-06-24
EP4039279A4 (en) 2023-11-01
JPWO2021066175A1 (cg-RX-API-DMAC7.html) 2021-04-08
US20220370630A1 (en) 2022-11-24
WO2021066175A1 (ja) 2021-04-08

Similar Documents

Publication Publication Date Title
CN108350022B (zh) 聚乙二醇缀合的糖皮质激素前体药物及其组合物和方法
JP6144383B2 (ja) 薬物送達系の構成成分の一時的コンジュゲーションのための調整可能な生分解性リンカー分子、及びそれを用いて調製される薬物送達系
JP2025094276A (ja) 膀胱の粘膜下組織への医薬品有効成分の経粘膜的送達システム、医薬組成物、及び膀胱疾患処置剤
HU216636B (hu) Eljárás epesavszármazékok előállítására
CA2625532C (en) Agent for applying to mucosa containing a hydrophobic group binding type glycosaminoglycan
JP2019059951A (ja) グリコサミノグリカン誘導体及びその製造方法
US10953037B2 (en) Chondroitin sulfate derivative and agent for treating bladder diseases
EP3020417A1 (en) Pharmaceutical composition for respiratory administration
WO2005085294A1 (ja) ヒアルロン酸−メトトレキサート結合体
CN114430756B (zh) 担载短链脂肪酸酯的亲水-疏水性共聚物
JP2023513086A (ja) 炎症性疾患を処置するための胆汁酸-gcpii阻害剤コンジュゲート
HK40039515A (en) Chondroitin sulfate derivative and agent for treating bladder diseases
KR102462782B1 (ko) 환원반응성 일산화질소 공여 화합물 및 전달체 시스템
JP5201546B2 (ja) N‐アセチルシステイン抱合型胆汁酸、それを含有する医薬組成物及びその製造方法
CN1462752A (zh) 化疗药物-偕二膦酸偶联物及其合成方法和用途

Legal Events

Date Code Title Description
AA64 Notification of invalidation of claim of internal priority (with term)

Free format text: JAPANESE INTERMEDIATE CODE: A241764

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230922

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230922

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240730

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250306

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250331

R150 Certificate of patent or registration of utility model

Ref document number: 7660066

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150